Patents Assigned to Medical College of Ohio
-
Patent number: 7605130Abstract: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.Type: GrantFiled: November 6, 2007Date of Patent: October 20, 2009Assignee: Medical College of OhioInventors: Ragheb Assaly, John D. Dignam, Joseph I. Shapiro
-
Patent number: 7592422Abstract: The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic.Type: GrantFiled: March 4, 2003Date of Patent: September 22, 2009Assignee: Medical College of OhioInventors: Rafal Swiercz, Steven H. Selman, Jerzy Jankun, Joanna Chorostowska-Wynimko, Ewa Skrzypczak-Jankun
-
Patent number: 7348312Abstract: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.Type: GrantFiled: March 22, 2006Date of Patent: March 25, 2008Assignee: Medical College of OhioInventors: Ragheb Assaly, John D. Dignam, Joseph I. Shapiro
-
Patent number: 7262027Abstract: The present invention provides compositions of novel polypeptides and polynucleotides encoding the polypeptides, which polypeptides are useful for generating an immunological response in an individual and in therapeutic application of Coccidioides spp. infection.Type: GrantFiled: March 3, 2004Date of Patent: August 28, 2007Assignees: Medical College of Ohio, The Regents of the University of California, United States of America Represented by the Department of Veterans AffairsInventors: Garry T. Cole, Jieh-Juen Yu, Jianmin Xue, Chiung-Yu Hung, Kalpathi R. Seshan, Theo N. Kirkland, III
-
Publication number: 20060188908Abstract: The present invention is directed to methods and compositions for evaluating nucleic acids, methods of preparing such compositions, and applications and business methods employing such compositions and methods. In particular, the present invention provides business methods for operating a gene expression measurement service.Type: ApplicationFiled: January 23, 2006Publication date: August 24, 2006Applicants: Medical College of Ohio, Gene Express, Inc.Inventors: James Willey, Brad Austermiller, Erin Crawford, Charles Knight, Terry Osborn, Robert Zahorchak
-
Publication number: 20060188909Abstract: The present invention is directed to methods and compositions for evaluating nucleic acids, methods of preparing such compositions, and applications and business methods employing such compositions and methods. In particular, the present invention provides business methods for operating a gene expression measurement service.Type: ApplicationFiled: January 23, 2006Publication date: August 24, 2006Applicants: Medical College of Ohio, Gene Express, Inc.Inventors: James Willey, Brad Austermiller, Erin Crawford, Charles Knight, Terry Osborn, Robert Zahorchak
-
Publication number: 20060190192Abstract: The present invention is directed to methods and compositions for evaluating nucleic acids, methods of preparing such compositions, and applications and business methods employing such compositions and methods. In particular, the present invention provides business methods for operating a gene expression measurement service.Type: ApplicationFiled: January 23, 2006Publication date: August 24, 2006Applicants: Medical College of Ohio, Gene Express, Inc.Inventors: James Willey, Brad Austermiller, Erin Crawford, Charles Knight, Terry Osborn, Robert Zahorchak
-
Publication number: 20060183144Abstract: The present invention is directed to methods and compositions for evaluating nucleic acids, methods of preparing such compositions, and applications and business methods employing such compositions and methods. In particular, the present invention provides business methods for operating a gene expression measurement service.Type: ApplicationFiled: January 23, 2006Publication date: August 17, 2006Applicants: Medical College of Ohio, Gene Express, Inc.Inventors: James Willey, Brad Austermiller, Erin Crawford, Charles Knight, Terry Osborn, Robert Zahorchak
-
Patent number: 7037895Abstract: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.Type: GrantFiled: March 26, 2002Date of Patent: May 2, 2006Assignee: Medical College of OhioInventors: Ragheb Assaly, John D. Dignam, Joseph I. Shapiro
-
Publication number: 20050260233Abstract: The present invention provides compositions of attenuated fungal mutants and polynucleotide sequences used to transform fungal strains by gene deletions or gene replacements, which are useful for generating an immunological response in human and animals and in therapeutic applications of infections due to pathogenic Coccidioides spp. fungi, such as C. immitis or C. posadasii.Type: ApplicationFiled: April 7, 2005Publication date: November 24, 2005Applicant: MEDICAL COLLEGE OF OHIOInventors: Garry Cole, Charles Okeke, Chiung-Yu Hung
-
Publication number: 20040181046Abstract: The present invention provides compositions of novel polypeptides and polynucleotides encoding the polypeptides, which polypeptides are useful for generating an immunological response in an individual and in therapeutic application of Coccidioides spp. infection.Type: ApplicationFiled: March 3, 2004Publication date: September 16, 2004Applicant: MEDICAL COLLEGE OF OHIOInventors: Garry T. Cole, Jieh-Juen Yu, Jianmin Xue, Chiung-Yu Hung, Kalpathi R. Seshan, Theo N. Kirkland
-
Publication number: 20040038284Abstract: This invention is based on the discovery that the type II TGF&bgr; receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.Type: ApplicationFiled: August 21, 2003Publication date: February 26, 2004Applicants: Case Western Reserve University, Medical College of OhioInventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson
-
Patent number: 6630326Abstract: This invention is based on the discovery that the type II TGF&bgr; receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.Type: GrantFiled: June 13, 2001Date of Patent: October 7, 2003Assignees: Case Western Reserve University, Medical College of OhioInventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson
-
Publication number: 20020106380Abstract: The present invention provides bacterial plasymids and recombinant SOW proteins that are useful as antigens for serodiagnosis of coccidiomycosis.Type: ApplicationFiled: May 7, 2001Publication date: August 8, 2002Applicant: Medical College of OhioInventors: Chiung-Yu Hung, Garry T. Cole
-
Publication number: 20020015693Abstract: The present invention relates to a method of modulating an immune response to a T-cell or thymus independent antigen in a host (e.g., mammalian, including human), comprising administering to the host an effective amount of interleukin-12 (IL-12) and the T-cell independent antigen. In one embodiment, the present invention relates to a method of inducing an immune response to a TI antigen in a host (e.g., mammalian, including human), which comprises administering to the host an effective amount of interleukin-12 (IL-12) and the TI antigen. In another embodiment, the present invention relates to a method of enhancing an immune response against a TI antigen in a host, which comprises administering to the host an effective amount of IL-12 and the TI antigen. The methods of the present invention can be used, for example, to induce and or enhance a humoral immune response (IgG2a and/or IgG3 humoral immune response).Type: ApplicationFiled: August 8, 2001Publication date: February 7, 2002Applicant: The Medical College of OhioInventors: Dennis W. Metzger, Renee M. Buchanan
-
Patent number: 6303114Abstract: The present invention relates to a method of modulating an immune response to a T-cell or thymus independent antigen in a host (e.g., mammalian, including human), comprising administering to the host an effective amount of interleukin-12 (IL-12) and the T-cell independent antigen. In one embodiment, the present invention relates to a method of inducing an immune response to a TI antigen in a host (e.g., mammalian, including human), which comprises administering to the host an effective amount of interleukin-12 (IL-12) and the TI antigen. In another embodiment, the present invention relates to a method of enhancing an immune response against a TI antigen in a host, which comprises administering to the host an effective amount of IL-12 and the TI antigen. The methods of the present invention can be used, for example, to induce and or enhance a humoral immune response (IgG2a and/or IgG3 humoral immune response).Type: GrantFiled: March 5, 1998Date of Patent: October 16, 2001Assignee: The Medical College of OhioInventors: Dennis W. Metzger, Renee M. Buchanan
-
Patent number: 6291237Abstract: This invention is based on the discovery that the type II TGF&bgr; receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.Type: GrantFiled: January 29, 1999Date of Patent: September 18, 2001Assignees: Case Western Reserve University, Medical College of OhioInventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson
-
Patent number: 6075128Abstract: The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.Type: GrantFiled: February 2, 1998Date of Patent: June 13, 2000Assignee: Medical College of OhioInventor: Ervin Faulmann
-
Patent number: 6025351Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl, an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, or a monoclonal antibody moiety which is attached to the adduct moiety through a carbonyl which is a part of an amide produced by reaction between an amine function of a monoclonal antibody and a CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.Type: GrantFiled: November 26, 1997Date of Patent: February 15, 2000Assignees: University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5985264Abstract: The present invention relates to a method of inducing a Th1-like response against a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen. Also encompassed by the present invention is a method of overcoming suppression of interferon-.gamma. (IFN-.gamma.) expression in a neonatal host due to exposure of the neonatal host to a pathogen or an antigen, which comprises administering to the neonatal host an effective amount of IL-12 and the antigen. The present invention also relates to a method of enhancing the cytokine expression against or in response to a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen.Type: GrantFiled: March 5, 1998Date of Patent: November 16, 1999Assignee: The Medical College of OhioInventors: Dennis W. Metzger, Bernard P. Arulanandam